αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence.
Cellular therapy
Immunology
Molecular biology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
31
03
2023
revised:
25
07
2023
accepted:
29
08
2023
medline:
18
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
Adoptive cell therapy using allogeneic γδ-T cells is a promising option for off-the-shelf T cell products with a low risk of graft-versus-host disease (GVHD). Long-term persistence may boost the clinical development of γδ-T cell products. In this study, we found that genetically modified Vγ9
Identifiants
pubmed: 37720098
doi: 10.1016/j.isci.2023.107802
pii: S2589-0042(23)01879-5
pmc: PMC10502403
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107802Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Blood. 2020 Sep 17;136(12):1407-1418
pubmed: 32483603
Cancer Discov. 2018 Aug;8(8):944-957
pubmed: 29891538
Cancers (Basel). 2021 Dec 30;14(1):
pubmed: 35008348
Surg Today. 2011 May;41(5):606-11
pubmed: 21533930
J Exp Med. 2013 Aug 26;210(9):1807-21
pubmed: 23940257
Nat Immunol. 2005 Aug;6(8):785-92
pubmed: 15980863
Science. 2021 Jun 4;372(6546):
pubmed: 34083463
J Transl Med. 2014 Feb 15;12:45
pubmed: 24528541
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
J Exp Med. 2010 Jun 7;207(6):1223-34
pubmed: 20457759
Cell Mol Immunol. 2021 Feb;18(2):427-439
pubmed: 32939032
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35768164
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
Mol Cancer. 2012 Oct 09;11:76
pubmed: 23043612
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
Nat Commun. 2020 Jun 5;11(1):2857
pubmed: 32504069
Immunity. 2012 Jan 27;36(1):68-78
pubmed: 22206904
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
Science. 2021 Oct 15;374(6565):eabe9977
pubmed: 34648346
J Exp Med. 2007 Oct 29;204(11):2747-57
pubmed: 17954567
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Blood. 2015 Jun 25;125(26):4017-23
pubmed: 25999455
Front Immunol. 2022 May 06;13:889051
pubmed: 35603176
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8
pubmed: 9050879
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819831068
pubmed: 30798772
Int J Cancer. 2001 Jun 15;92(6):856-60
pubmed: 11351307
Cytotherapy. 2017 Apr;19(4):473-485
pubmed: 28188072
J Immunol. 2010 May 1;184(9):4936-46
pubmed: 20351194
Antibodies (Basel). 2021 Apr 26;10(2):
pubmed: 33925949
Biochem Soc Trans. 2021 Nov 1;49(5):1985-1995
pubmed: 34515758
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Int J Mol Sci. 2021 Aug 18;22(16):
pubmed: 34445615
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Blood. 2014 Jun 12;123(24):3750-9
pubmed: 24782509
Nat Med. 2010 May;16(5):565-70, 1p following 570
pubmed: 20400962
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16916-21
pubmed: 20837541
Int J Cancer. 2023 Jun 15;152(12):2554-2566
pubmed: 36727538
Cancer Cell. 2015 Oct 12;28(4):415-428
pubmed: 26461090
J Vasc Interv Radiol. 2022 Jan;33(1):19-27.e3
pubmed: 34600129
Cancer Res. 2006 Mar 15;66(6):3331-7
pubmed: 16540688
Gene Ther. 2009 May;16(5):620-8
pubmed: 19242528
Nat Immunol. 2021 Feb;22(2):179-192
pubmed: 33462452
Adv Cancer Res. 2006;95:1-30
pubmed: 16860654
BMC Cancer. 2017 Aug 17;17(1):551
pubmed: 28818060
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Eur J Pharmacol. 2022 Mar 15;919:174803
pubmed: 35131312
Cancer Sci. 2018 Mar;109(3):587-599
pubmed: 29288540